ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 생물학적 제제 아웃소싱 시장 규모는 앞으로 수년간 급성장할 것으로 전망됩니다. 2029년까지 CAGR 13.4%로 확대되어 372억 8,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 신흥 시장의 성장, 개인화 의료, 전략적 제휴, 생물학적 제제의 특허 만료 등에 기인하고 있습니다. 예측기간의 주요 동향으로는 기술의 진보, 아웃소싱의 복잡화, 바이오시밀러 시장의 확대, 데이터 분석의 통합, 공급망의 회복력 등이 있습니다.
향후 5년간의 성장률을 13.4%로 예측한 것은 지난 예측으로부터 0.1% 소폭 감소를 반영한 것입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 관세 부과로 인해 한국과 이탈리아에서 수입되는 충전 마감 서비스 및 안정성 검사 비용이 상승하고, 생물학적 제제의 제조가 지연되고, 제조 비용이 상승할 수 있으므로 미국 바이오 의약품이 혼란스러울 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향에 의해 그 영향은 보다 광범위하게 되는 것으로 예측됩니다.
생물학적 제제 아웃소싱 시장은 암 환자 수 증가에 견인되어 성장을 이루려고 합니다. 암은 조절할 수 없는 세포 증식을 특징으로 하는 다양한 질환군이며, 단일클론항체나 면역요법 등의 생물학적 요법의 개발에는 전문적인 전문지식과 자원이 필요합니다. 생물학적 제제 아웃소싱은 다양한 유형의 암 진단 및 치료에 필수적인 이러한 치료법의 개발, 제조 및 임상 공급에 필요한 인프라를 제공하는 데 필수적인 존재입니다. 예를 들어 미국 바이오테크놀러지 정보센터(National Center for BIoTechnology Information)는 2023년 1월 미국에서 새롭게 195만 8,310명의 암 환자가 발생하여 60만 9,820명의 암 관련 사망이 예측된다고 보고하고 있습니다. 암의 유병률은 2040년까지 2,950만명의 신규 사례와 1,640만명의 사망으로 증가할 것으로 예상되고 있으며, 암이 야기하는 증대하는 과제에 대처하는데 있어서, 생물학적 제제 아웃소싱의 역할이 강조되고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 생물학적 제제 아웃소싱 시장 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 생물학적 제제 아웃소싱 시장 : 성장률 분석
세계의 생물학적 제제 아웃소싱 시장 실적 : 규모와 성장, 2019-2024년
세계의 생물학적 제제 아웃소싱 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 생물학적 제제 아웃소싱 시장 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 생물학적 제제 아웃소싱 시장 : 제품 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
항체
재조합
백신
단백질
기타
세계의 생물학적 제제 아웃소싱 시장 : 공급원별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
인간
미생물
기타
세계의 생물학적 제제 아웃소싱 시장 : 용도별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
종양학
세포 및 유전자 치료
혈액 및 혈액 관련 제품 개발
백신 개발
줄기세포 연구
기타
세계의 생물학적 제제 아웃소싱 시장 : 최종 사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제약산업
바이오테크놀러지 산업
계약 개발 제조 조직(CDMO)
세계의 생물학적 제제 아웃소싱 시장 : 항체별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
단클론항체
다클론항체
세계의 생물학적 제제 아웃소싱 시장 : 재조합별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
재조합 단백질
재조합 DNA 제품
세계의 생물학적 제제 아웃소싱 시장 : 백신별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
치료 백신
예방 백신
세계의 생물학적 제제 아웃소싱 시장 : 단백질별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
효소
호르몬
세계의 생물학적 제제 아웃소싱 시장 : 기타별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
유전자 치료
세포치료
바이오시밀러
제7장 지역별/국가별 분석
세계의 생물학적 제제 아웃소싱 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 생물학적 제제 아웃소싱 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
생물학적 제제 아웃소싱 시장 : 경쟁 구도
생물학적 제제 아웃소싱 시장 : 기업 프로파일
AbbVie Inc.
Thermo Fisher Scientific Inc.
Boehringer Ingelheim GmbH
Lonza Group Ag
Catalent Inc.
제31장 기타 주요 기업 및 혁신 기업
Sartorius Stedim BIoTech SA
Charles River Laboratories International Inc.
WuXi Biologics Inc.
Samsung Biologics Co. Ltd.
Emergent BioSolutions Inc.
CordenPharma GmbH
Ajinomoto Bio-Pharma Services
Syngene International Limited
Rentschler Biopharma SE
Albany Molecular Research Inc.
KBI Biopharma Inc.
Fujifilm Diosynth BIoTechnologies Inc.
Avid Bioservices Inc.
BioVectra Inc.
ProBioGen AG
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 전략
생물학적 제제 아웃소싱 시장(2029년) : 새로운 기회를 제공하는 국가
생물학적 제제 아웃소싱 시장(2029년) : 새로운 기회를 제공하는 부문
생물학적 제제 아웃소싱 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
JHS
영문 목차
영문목차
Biologics outsourcing in the pharmaceutical industry involves pharmaceutical companies collaborating with external vendors or contract manufacturing organizations (CMOs) to delegate different aspects of biologic drug development, manufacturing, and supply chain management. This strategic approach is employed for various purposes within the pharmaceutical sector, specifically in relation to the development, manufacturing, and management of biological drugs.
The primary product types associated with biologics outsourcing include antibodies, recombinants, vaccines, proteins, and others. Antibodies are immune system-produced defense proteins, also known as antigens, formed in response to the presence of foreign material. These biologics can be derived from human, microbial, and other sources and find applications in areas such as oncology, cellular and gene therapy, blood and blood-related product development, vaccine development, stem cell research, among others. Biologics outsourcing is utilized by diverse end users, including pharmaceutical industries, biotechnology industries, and contract development and manufacturing organizations (CDMO).
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The biologics outsourcing market research report is one of a series of new reports from The Business Research Company that provides biologics outsourcing market statistics, including the biologics outsourcing industry's global market size, regional shares, competitors with a biologics outsourcing market share, detailed biologics outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the biologics outsourcing industry. This biologics outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The biologics outsourcing market size has grown rapidly in recent years. It will grow from $20.06 billion in 2024 to $22.58 billion in 2025 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to increasing R&D costs, regulatory pressure, demand for specialized expertise, globalization.
The biologics outsourcing market size is expected to see rapid growth in the next few years. It will grow to $37.28 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to emerging markets' growth, personalized medicine, strategic alliances, biological drug patent expirations. Major trends in the forecast period include advancements in technology, increased outsourcing complexity, biosimilars market expansion, data analytics integration, supply chain resilience.
The forecast of 13.4% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. biopharma by increasing costs for fill-finish services and stability testing imported from South Korea and Italy, potentially delaying biologics manufacturing and raising production expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The biologics outsourcing market is poised for growth, driven by the increasing number of cancer cases. Cancer, a diverse group of illnesses characterized by uncontrolled cell growth, demands specialized expertise and resources for developing biologic therapies such as monoclonal antibodies and immunotherapies. Biologics outsourcing is integral in providing the necessary infrastructure for the development, manufacturing, and clinical supply of these therapies, crucial for diagnosing and treating various cancer types. For instance, the National Center for Biotechnology Information reported 1,958,310 new cancer cases in the United States in January 2023, with a projected 609,820 cancer-related deaths. The prevalence of cancer is expected to escalate to 29.5 million new cases and 16.4 million deaths by 2040, emphasizing the role of biologics outsourcing in addressing the growing challenges posed by cancer.
The biologics outsourcing market is anticipated to be supported by the rise in chronic diseases and disabilities. Chronic conditions necessitate ongoing medical attention, and biologics prove effective in managing such complex health issues. Pharmaceutical and biotechnology companies are increasingly turning to outsourcing for specialized expertise in developing targeted treatments. The National Library of Medicine estimates a 99.5% increase in people aged 50 and older with at least one chronic illness, reaching 142.66 million in 2050. Additionally, the number of individuals with multimorbidity is projected to rise by 91.16% to 14.968 million in 2050. This surge in chronic diseases underscores the significance of biologics outsourcing in meeting the demands of intricate medical conditions.
A notable trend in the biologics outsourcing market is the emphasis on developments in biologics. Major companies are leveraging new technologies to sustain their market positions. For instance, Abzena, Alira Health, and Oncodesign launched DRIVE-Biologics, a consortium dedicated to biologic drug discovery and development programs. This collaborative effort streamlines information sharing and program deliverables, minimizing risks associated with biologics development. The partnership covers all stages, from biological discovery to clinical and commercial manufacturing, reflecting the commitment to advancing the field of biologics.
Companies in the biologics outsourcing market are focusing on establishing new Contract Development and Manufacturing Organizations (CDMOs) to maintain their market presence. Tanvex BioPharma USA Inc. introduced Tanvex CDMO in October 2023, offering end-to-end services for the development and manufacturing of biologics. Located in San Diego's biotech hub, Tanvex CDMO features state-of-the-art facilities, including R&D centers, GMP manufacturing suites, QC laboratories, and a GMP warehouse. With a proven track record, Tanvex CDMO aims to support early-stage companies in advancing biologics from conceptualization to commercialization.
In June 2022, Asahi Kasei Medical acquired Bionova Scientific LLC, expanding its bioprocess business to include biopharmaceutical contract development and manufacturing. Bionova Scientific LLC, a biologics CDMO, enhances Asahi Kasei Medical's capabilities in biologic drug development, manufacturing, and supply chain management, contributing to the broader landscape of biologics outsourcing.
Major companies operating in the biologics outsourcing market include AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc., Sartorius Stedim Biotech S.A., Charles River Laboratories International Inc., WuXi Biologics Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., CordenPharma GmbH, Ajinomoto Bio-Pharma Services, Syngene International Limited, Rentschler Biopharma SE, Albany Molecular Research Inc., KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies Inc., Avid Bioservices Inc., BioVectra Inc., ProBioGen AG, ABL Inc., Vibalogics GmbH, JHL Biotech Inc., Goodwin Biotechnology Inc., Crown Bioscience Inc., Cytovance Biologics Inc., LakePharma Inc., AGC Biologics GmbH, Biomay AG, Polpharma Biologics S.A.
North America was the largest region in the biologics outsourcing market in 2024. The regions covered in the biologics outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the biologics outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The biologics outsourcing market includes revenues earned by entities through cell line development, contract research services, and optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Biologics Outsourcing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on biologics outsourcing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for biologics outsourcing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The biologics outsourcing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Antibodies; Recombinant; Vaccines; Protein; Other Products
2) By Source: Human; Microbial; Other Source
3) By Application: Oncology; Cellular And Gene Therapy; Blood And Blood-Related Products Development; Vaccine Development; Stem Cell Research; Other Applications
4) By End User: Pharmaceutical Industries; Biotechnology Industries; Contract Development And Manufacturing Organization(CDMO)
Subsegments:
1) By Antibodies: Monoclonal Antibodies; Polyclonal Antibodies
2) By Recombinant: Recombinant Proteins; Recombinant DNA Products
3) By Vaccines: Therapeutic Vaccines; Preventive Vaccines
4) By Protein: Enzymes; Hormones; Cytokines
5) By Other Products: Gene Therapies; Cell Therapies; Biosimilars
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Biologics Outsourcing Market Characteristics
3. Biologics Outsourcing Market Trends And Strategies
4. Biologics Outsourcing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Biologics Outsourcing Growth Analysis And Strategic Analysis Framework
5.1. Global Biologics Outsourcing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Biologics Outsourcing Market Growth Rate Analysis
5.4. Global Biologics Outsourcing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Biologics Outsourcing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Biologics Outsourcing Total Addressable Market (TAM)
6. Biologics Outsourcing Market Segmentation
6.1. Global Biologics Outsourcing Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antibodies
Recombinant
Vaccines
Protein
Other Products
6.2. Global Biologics Outsourcing Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Human
Microbial
Other Source
6.3. Global Biologics Outsourcing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology
Cellular And Gene Therapy
Blood And Blood-Related Products Development
Vaccine Development
Stem Cell Research
Other Applications
6.4. Global Biologics Outsourcing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical Industries
Biotechnology Industries
Contract Development And Manufacturing Organization (CDMO)
6.5. Global Biologics Outsourcing Market, Sub-Segmentation Of Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Polyclonal Antibodies
6.6. Global Biologics Outsourcing Market, Sub-Segmentation Of Recombinant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Recombinant Proteins
Recombinant DNA Products
6.7. Global Biologics Outsourcing Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Therapeutic Vaccines
Preventive Vaccines
6.8. Global Biologics Outsourcing Market, Sub-Segmentation Of Protein, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzymes
Hormones
6.9. Global Biologics Outsourcing Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gene Therapies
Cell Therapies
Biosimilars
7. Biologics Outsourcing Market Regional And Country Analysis
7.1. Global Biologics Outsourcing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Biologics Outsourcing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
